Sarah Verhoeff

148 Chapter 8 24. Borm FJ, Smit J, Oprea-Lager DE, et al. Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Cancers (Basel). 2021;13(12). 25. Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. The value of (18)F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(2):428-448. 26. Ferdinandus J, Zaremba A, Zimmer L, et al. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma. Cancer Imaging. 2022;22(1):11. 27. Schank TE, Forschner A, Sachse MM, et al. Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers (Basel). 2021;13(11). 28. Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84-91.

RkJQdWJsaXNoZXIy MTk4NDMw